

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

**SCHEDULE 14A
(RULE 14a-101)**

**INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION**

**Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.)**

Filed by the Registrant

Filed by a Party other than the Registrant

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to §240.14a-12

ADAMIS PHARMACEUTICALS CORPORATION

(Name of Registrant as Specified In Its Charter)

Not Applicable

(Name of Person(s) Filing Proxy Statement, if other than Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:



This is an Important Message for Adamis Pharmaceuticals Corp. Stockholders

Your vote is needed for the Annual Meeting of Adamis Stockholders

WHEN: SEPTEMBER 3, 2020

OBJECTIVE: VOTE FOR THE FOLLOWING SHAREHOLDER PROPOSALS:



ADAMIS

Pharmaceuticals Corporation

Providing Solutions for a Changing Healthcare Landscape

- **PROPOSAL 2:** To approve an amendment to increase the number of shares of common stock authorized to be issued by the Company from 100,000,000 to 200,000,000.
- **PROPOSAL 3:** To approve a proposal to authorize the board of directors in its discretion to effect a reverse stock split of our outstanding shares of common stock.

Adamis Stockholders: Your Vote Is Needed — Now!

The Board of Directors recommends you vote FOR proposals 2 and 3 at the annual meeting of stockholders, which was adjourned and will reconvene on September 3, 2020. The proposals will increase the number of shares of common stock authorized to be issued by the Company from 100,000,000 to 200,000,000, and authorize the board of directors in its discretion to effect a reverse stock split of our outstanding shares of common stock.

WHY YOU SHOULD SUPPORT THE INCREASE IN SHARES OF ADAMIS COMMON STOCK AND APPROVE A REVERSE STOCK SPLIT:

- An increase in the authorized shares of common stock (Proposal 2) gives the management various options while running the business, including: (1) ability to acquire assets to increase shareholder value, and (2) ability to raise capital, if necessary.
- Approval of the reverse stock split (Proposal 3) will help the company, if necessary, maintain and/or meet NASDAQ Listing Requirements and also make shares available for future issuance for necessary or advisable corporate purposes.



ADAMIS

Pharmaceuticals Corporation

Providing Solutions for a Changing Healthcare Landscape

Your vote is important.

Please CALL the Company's
Investor Relations Department at:
(858) 412-7951